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Abstract
Background: Type 1 regulatory T (Tr1) cells, characterized by the secretion of high levels of the anti-inflammatory cytokine
interleukin-10 (IL-10), play an important role in the regulation of autoimmune diseases and transplantation. However,
effective strategies that specifically induce Tr1 cells in vivo are limited. Furthermore, the pathways controlling the induction
of these cells in vivo are not well understood.
Methodology/Principal Findings: Here we report that nasal administration of anti-CD3 antibody induces suppressive Tr1
cells in mice. The in vivo induction of Tr1 cells by nasal anti-CD3 is dependent on IL-27 produced by upper airway resident
dendritic cells (DCs), and is controlled by the transcription factors aryl hydrocarbon receptor (AHR) and c-Maf. Subsequently,
IL-21 acts in an autocrine fashion to expand and maintain the Tr1 cells induced in vivo by nasally administered anti-CD3.
Conclusions/Significance: Our findings identify a unique approach to generate Tr1 cells in vivo and provide insights into
the mechanisms by which these cells are induced.
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Introduction
The generation of functional regulatory T cells in vivo is a major
goal for the treatment of immune-mediated diseases. Tr1 cells are
regulatory T cells characterized by a cytokine profile that is distinct
fromT helper 1 (Th1), Th2, Th3 and Foxp3+regulatory T cells(Treg)
[1]. Tr1 cells do not constitutively express the transcription factor
forkhead box p3 (Foxp3), which is a lineage specific marker for both
naturally occurring and induced CD4+CD25+ regulatory T cells [2].
Upon T-cell receptor (TCR) mediated activation, Tr1 cells produce
high levels of IL-10 and transforming growth factor-beta (TGF-b),
low levels of interferon-gamma (IFN-c) and almost no IL-2 or IL-4.
The mechanism of in vitro suppression by Tr1 cells is linked to
IL-10 [3,4] as neutralization of IL-10 by monoclonal antibodies
typically reverses suppression. Upon TCR stimulation, Tr1 cells
can mediate bystander suppression by the local release of IL-10
and TGF-b that act on both antigen presenting cells (APCs) and T
cells to suppress co-stimulatory molecule expression and pro-
inflammatory cytokine production, respectively [5].
Tr1 cells can be generated in vitro from naı ¨ve precursors in
response to different cytokine milieus. Early studies in which
antigen-specific Tr1 cells were induced in vitro by repeated TCR
stimulation in the presence of high doses of IL-10 suggested that
IL-10 plays an important role in Tr1 cell differentiation [1].
However, it has been recently shown that IL-10 does not play a
crucial role during the differentiation of Tr1 cells in vivo [6]. We
[7] and others [8] have identified a critical function for IL-27 in
the induction of Tr1 cells. Specifically, we found that DC-derived
IL-27 is required for the differentiation of IL-10-secreting Tr1
cells, this process is amplified by TGF-b [6,7].
Although the generation of Tr1 cells potentially constitutes a new
therapeutic approach for immune-mediated diseases, methods for
theinductionofTr1cellsinvivoarestillmissing.Herewereportthat
nasal anti-CD3 triggers the differentiation of suppressive Tr1 cells by
a mechanism dependent on the production of IL-27 by upper
airway-resident DCs. Furthermore, the generation of Tr1 cells in
vivo is controlled by AHR and c-Maf in T cells, and the autocrine
effects of IL-21. Thus, nasally administered anti-CD3 might
constitute a new approach for the therapeutic induction of Tr1 cells.
Results
Nasal administration of anti-CD3 induces suppressive Tr1
cells
We used tiger mice [9] carrying a green fluorescent reporter
(GFP) reporter inserted immediately before the polyadenylation
site of the il10 gene to investigate the effect of nasal administration
of anti-CD3 on CD4+ IL-10+ T cells. We found that the
frequency of CD4+CD25-GFP(IL-10)+ cells was upregulated
following nasal treatment with anti-CD3 (Figure 1A). Upon
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23618Figure 1. Nasal anti-CD3 induces suppressive Tr1 cells. A. Tiger mice were nasally treated with IC (clear bars) or anti-CD3 (filled bars) and
72 hrs after the last nasal dose GFP(IL-10) expression by CD4+ T cells in CLN was examined by flow cytometry. This experiment was repeated 4 times
with same results. B and C. CD4+CD25-GFP-, CD4+CD25+GFP- or CD4+CD25-GFP+ T cells were sorted from CLN of Tiger mice nasally treated with IC
(clear bar) or anti-CD3 (filled bar). Sorted T cells were stimulated in vitro with plate bound anti-CD3 and anti-CD28 antibodies (1 mg/ml each) and IL-10
(B) and (C) IFN-c were detected in the supernatants by ELISA. Error bars represent standard deviations and P values were calculated by t-test. D. The
percentage of CD4+CD25-LAP+ T cells that express IL-10 following nasal anti-CD3 was assessed by intracellular staining. Each symbol represents an
individual mouse. E. FACS-sorted Tr1 cells (CD4+CD25-GFP(IL-10)+, clear bar) from CLN of nasal anti-CD3 treated Tiger mice or IL-27 in vitro
differentiated Tr1 cells (filled bar) were used in a standard suppression assay with naı ¨ve CD4+CD25-GFP- responder T cells at various ratios. To test the
role of IL-10 in in vitro suppression, IC or anti-IL-10 (50 mg/ml) neutralizing antibodies were added to co-cultures at 1:1 ratio.
doi:10.1371/journal.pone.0023618.g001
In Vivo Tr1 Cell Generation Requires DCs and AHR
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23618activation with anti-CD3 in vitro, FACS sorted CD4+CD25-
GFP(IL-10)+ T cells secreted IL-10 and IFN-c (Figure 1B). This
cytokine pattern is consistent with a Tr1 cell phenotype [10], and
was not seen when CD4+CD25-GFP(IL-10)- naive T cells or
CD4+CD25+GFP(IL-10)- T cells were sorted from anti-CD3
treated mice and activated in vitro (Figure 1B).
We have previously shown that the suppressive T cells induced
by the oral administration of anti-CD3 are characterized by the
expression of membrane-bound TGF-b (LAP). In accordance with
our previous observations, we found that the CD4+CD25-GFP(IL-
10)+ T cells induced by the nasal administration of anti-CD3 were
mostly LAP+ (Figure 1c).
We next studied the suppressive activity of the CD4+CD25-
GFP(IL-10)+ T cells induced by nasal treatment with anti-CD3.
We found that CD4+CD25-GFP(IL-10)+ T cells isolated from
anti-CD3 treated mice suppressed the proliferation of responder
CD4+CD25-GFP- T cells (Figure 1D). The suppressive activity
of the CD4+CD25-GFP(IL-10)+ T cells induced by the nasal
administration of anti-CD3 was mediated by IL-10, because it
could be abrogated with IL-10 specific antibodies (Figure 1D).
Similar results were observed when we analyzed the suppressive
activity of CD4+ GFP(IL-10)+ Tr1 cells induced in vitro with IL-
27 (Figure 1D). Taken together these data demonstrate that nasal
anti-CD3 generates suppressive LAP+ Tr1 cells.
IL-27 secreted by upper airway-resident DCs is required
for the induction of Tr1 cells by nasal anti-CD3
DCs play an important role in the activation and polarization of
T cells in vivo [11]. Indeed, we and others have recently described
that DC-derived IL-27 [7,8] and TGF-b[6,7] play a critical role
for in the differentiation of Tr1 cells. To investigate the role of
DCs in the generation of Tr1 cells in vivo, we studied the effect of
nasal anti-CD3 on the production of cytokines by CD11c+ and
CD11b+ cells in the cervical lymph node (CLN). We found that
nasal administration of anti-CD3 induces a unique cytokine profile
in CD11c+ DCs, characterized by the expression of IL-10, TGF-b
and IL-27 (Figure 2A). This profile was not observed in CD11b+
macrophages (Figure 2B) or splenic or mesenteric lymph node-
derived DCs (not shown).
We thus examined the requirement for upper airway resident
DCs in the generation of IL-10-secreting LAP+ Tr1 cells, using
transgenic mice in which the CD11c promoter controls the
expression of a diphtheria toxin receptor (DTR)-GFP cassette
[12]. Nasal administration of diphtheria toxin (DT) led to a
significant depletion of CD11c+ DCs in the CLN but not in spleen
(Figure 2C). Moreover, depletion of CLN resident DCs by nasal
DT abolished the generation of the IL-10-secreting CD4+CD25-
LAP+ T cells induced by nasal anti-CD3 (Figure 2D).
To further investigate the role of DCs in the differentiation of
IL-10-secreting Tr1 cells, we co-cultured naı ¨ve (CD4+CD25-GFP-
) Tiger T cells with CD11c+ DCs or CD11b+ macrophages
harvested from the CLN of mice treated with nasal anti-CD3. Co-
incubation with DCs from mice treated with nasal anti-CD3
upregulated the expression of GFP (IL-10) and LAP in T cells
(Figure 2E). We then used neutralizing antibodies to IL-27 and/
or TGF-b to investigate the mechanisms of Tr1 induction by DCs
taken from anti-CD3 treated mice. We found that the induction of
GFP (IL-10) and LAP expression by Tr1 cells in vitro was
dependent both on DC-derived IL-27 and TGF-b signaling as
neutralizing antibodies to IL-27 and/or TGF-b suppressed the
expression of both GFP (IL-10) and LAP by Tr1 cells (Figure 2F).
Taken together, these findings suggest that local DCs promote the
generation of LAP+ Tr1 cells by nasal anti-CD3 via the secretion
of IL-27 and TGF-b.
Tr1 cells induced by nasal anti-CD3 express ahr, cmaf, il21
and il21r
The transcription factor c-Maf plays an important role in the
regulation of il10 expression [13,14,15,16]. We have recently
shown that c-Maf interacts with the transcription factor AHR to
control the expression of il10 and the autocrine Tr1 growth factor
il21 [17]. AHR and cMAF also cooperate to control the expression
of human IL10 [18]. To investigate the molecular mechanisms
leading to the differentiation of Tr1 cells in vivo in response to the
nasal administration of anti-CD3, we studied the expression of maf,
ahr, il21 and il21r; was also analyzed the expression of il10, ifng and
foxp3. Naı ¨ve T cells and CD4+CD25-GFP(IL-10)+ Tr1 cells were
FACS-sorted from tiger mice treated with nasal anti-CD3, Foxp3+
nTregs were isolated from Foxp3 GFP knock-in transgenic mice
[19], and gene expression was analyzed by quantitative PCR. We
found that freshly isolated CD4+CD25-GFP(IL-10)+ Tr1 cells
induced by treatment with nasal anti-CD3 consistently expressed
high levels of il10 and also some ifng, however foxp3 expression was
undetectable (Figure 3A). Moreover, freshly isolated Tr1 cells
from nasal anti-CD3 treated mice expressed significant levels of ahr
(Figure 3B) and maf (Figure 3C) as well as il21 (Figure 3D) and
il21r (Figure 3E). Thus the Tr1 cells induced by treatment with
nasal anti-CD3 express the transcription factors AHR, c-Maf, and
also the autocrine growth factor IL-21.
AHR signaling and IL-21 mediate the induction of Tr1
cells by nasal anti-CD3
To investigate the role of AHR in the generation of Tr1 cells in
vivo we generated tiger mice carrying a mutant AHR protein that
shows a reduced affinity for its ligands (Ahr
d) [20]. We thus studied
the frequency of Tr1 cells in the CLN following nasal anti-CD3 in
tiger and Ahr
d/tiger mice. Figure 4A shows that induction of
GFP(IL-10)+ Tr1 cells by nasal anti-CD3 is completely abolished
in the Ahr
d/tiger mice, thus AHR signaling is essential for the
generation of Tr1 cells in vivo in response to nasally administered
anti-CD3.
IL-21 is an autocrine growth factor for Tr1 cells [21,22]. We
have recently reported that AHR and c-Maf directly control the
production of IL-21 during the differentiation of Tr1 cells [17].
Thus, based on the expression of il21 and il21r by Tr1 cells
induced in response to the nasal administration of anti-CD3, we
investigated the role of IL-21 in the generation of Tr1 cells in vivo.
We first studied the effect of treating tiger mice with anti-CD3 co-
administered nasally with recombinant IL-21 or vehicle as control.
We found that the nasal co-administration of anti-CD3 with
recombinant IL-21 led to a significant increase in the generation of
Tr1 cells (Figure 4B). We then analyzed the induction of Tr1 cells
by nasal anti-CD3 in IL-21R 2/2 and wild type mice. We found
a significant impairment in the induction of Tr1 cells triggered by
nasal anti-CD3 in IL-21R 2/2 mice (Figure 4C). Thus, IL-21
plays an important role in the induction of Tr1 cells in vivo as a
result of treatment with nasal anti-CD3.
Tr1 cells induced by nasal anti-CD3 in an IL-27-
dependent manner control systemic autoimmunity
To investigate the role of IL-27 in the induction of Tr1 cells by
nasal anti-CD3, we backcrossed IL-27 receptora-deficient mice
onto the lupus prone lpr background (IL-27R2/2/lpr).
Figures 5A and 5B show that the generation of LAP+ Tr1 cells
following nasal administration of anti-CD3 is dependent on IL-27,
as no upregulation of LAP was seen in IL-27R2/2/lpr mice.
Concomitant with the deficient generation of LAP+ Tr1 cells, we
found that CD4+ T cells from IL-27R2/2/lpr mice given nasal
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12 upon in vitro stimulation with anti-CD3 (Figure 5B).
We next investigated the role of IL-27 and LAP+ Tr1 cells
induced by nasal anti-CD3 in the control of systemic autoimmu-
nity. IL-27R2/2/lpr mice developed spontaneous fatal autoim-
munity significantly earlier than MRL/lpr mice (Figure 5C,
compare green and black lines). This accelerated development of
fatal autoimmunity was associated with a progressive increase in
serum IgG autoantibodies to double stranded DNA (dsDNA)
(Figure 5D). Moreover, nasal anti-CD3 (three 5-day courses of
0.5 mg/day given at alternative weeks) significantly prolonged the
survival of MRL/lpr but not of IL-27R2/2/lpr mice (Figure 5C,
compare red and blue lines). Taken together, these data suggests
that IL-27 is required for the generation of suppressive LAP+ Tr1
cells following nasal administration of anti-CD3.
To confirm that the lack of protective effect of nasal anti-CD3 in
IL-27R2/2/lpr mice is linked to the defective induction of LAP+
Tr1 cells (Figures 5A and 5B) we performed adoptive transfer
experiments. The transfer of CLN CD4+ T cells from wild type
mice treated with nasal anti-CD3 protected IL-27R2/2/lpr
recipients from the development of fatal autoimmunity
(Figure 5E, compare blue and red lines). This protection was
associated with a significant reduction in the production of IgG
anti-dsDNA autoantibodies (Figure 5D). The suppression of
systemic autoimmunity in this adoptive transfer system was
dependent on LAP+ Tr1 cells, as protection was reversed by
Figure 2. In vivo induction of Tr1 cells is dependent on mucosal DC-derived IL-27 and TGF-b.A .CD11c+ DCs or B. CD11b+ macrophages
were positively selected from CLNs following nasal IC (clear bars) or anti-CD3 (filled bars) and used in quantitative RTPCR. This experiment was
repeated 3 times with same results. Error bars represent standard deviations and P values were calculated by t-test. C. CD11c DTR-GFP mice were
nasally treated with PBS or 500 ng of DT. CLNs and spleens were harvested 24 hrs following nasal DT. 10 mM frozen sections were stained with
Toprol-3. Pictures were taken at 640 magnification. D. CD11c DTR-GFP mice were nasally treated with anti-CD3 or DT followed anti-CD3. 72 hrs
following nasal treatment, CLN cells were stained with anti-CD4, anti-CD25 and anti-LAP antibodies for FACS. LAP staining on gated CD4+CD25- T
cells is shown. E. B6 mice were nasally treated with anti-CD3. CD11b+ macrophages (left column) or CD11c+ DCs (right column) were positively
selected from CLN at 72 hrs after the last nasal dose. Co-cultures of macrophages or DCs and CD4+CD25-GFP- naı ¨ve Tiger T cells were stimulated with
LPS (1 mg/ml) or FLT3 ligand (1 mg/ml) respectively and plate bound anti-CD3 (1 mg/ml) for 96 hrs. Cells were stained with anti-LAP antibody. FACs
plots shown here were on gated CD4+ lymphocytes. Representative FACs plots of 3 independent experiments are shown here. F. B6 mice were
nasally treated with anti-CD3. CD11c+ DCs were positively selected from CLN 72 hrs after the last nasal dose. Co-cultures of DCs and CD4+CD25-GFP-
naı ¨ve Tiger T cells were stimulated with 1 mg of FLT3 ligand and plate bound anti-CD3 in the presence of 10 mg/ml neutralizing antibody to TGF-b
and/or IL-27 for 96 hrs. Cells were stained with anti-LAP antibody. Representative FACs plots of 3 independent experiments are shown here.
doi:10.1371/journal.pone.0023618.g002
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compare yellow and red lines).
We found similar effects when the recipients of LAP+ Tr1 cells
were investigated in terms of autoantibody production
(Figure 5D) and IFN-c and IL-12 production (Figure 5F).
Thus, IL-27 mediates the induction of LAP+ suppressive Tr1 cells
following the nasal administration of anti-CD3 in the context of
ongoing inflammation.
Discussion
Tr1 cells are regulatory T cells that do not express Foxp3 and
suppress tissue inflammation, graft-versus-host disease and auto-
immunity in an IL-10 dependent manner. IL-27 plays a major role
in the differentiation of IL-10-secreting Tr1 cells [7,23]. Indeed,
we have recently demonstrated that IL-27 induces the expression
of the transcription factors AHR and c-Maf, which cooperate to
control the expression of il10 and of the autocrine Tr1 growth
factor il21 [17]. AHR and cMaf also cooperate to control the
expression of human Il10 [18].
Here we show that nasal administration of an anti-CD3
monoclonal antibody induces suppressive Tr1 cells. We found
that the induction of Tr1 cells is dependent on local DCs that
express IL-27, IL-10 and TGF-b as site-specific depletion of DCs
abolishes Tr1 cell generation by nasal anti-CD3. To our
knowledge, this is the first demonstration of an essential role of
upper airway-resident DCs in the generation of Tr1 cells in vivo.
Accumulating evidence suggests that resident DCs in mucosal
tissues possess unique features not shared by DCs in peripheral
lymphoid tissues [24]. Most notably is their ability to generate
regulatory T cells that suppress airway and gut inflammation in
mouse models of asthma [25] and inflammatory bowel disease
[26]. In support of these findings, it has been demonstrated that
resident DCs in lamina propria and mesenteric lymph nodes are
critical for the generation of Foxp3+ regulatory T cells in the gut
[27,28,29].
The upper airway mucosal DCs may be controlled by local
signals produced by the bronchial and intestinal epithelia. For
instance, in co-culture studies it has been shown that products of
epithelial cells condition DCs to promote Th2 immunity in an
allogeneic response [30]. It is possible that in the face of
continuous challenge from environmental antigens, mucosal
epithelial cells secrete cytokines that condition DCs modified to
promote the differentiation of Tr1 cells. Thus, similar to DCs
present in gut-associated lymphoid tissue [31,32], we show here
that DCs present in the nasal-associated lymphoid tissue also play
a physiologic role in the generation of regulatory T cells.
We used the Ahr
d/tiger mouse to investigate the molecular
mechanisms that mediate the induction of Tr1 cells by nasal anti-
CD3. We found that Tr1 cells induced by nasal anti-CD3 express
high levels of ahr, c-Maf, il21 and il21r. Furthermore, we
demonstrated that AHR and IL-21 are needed for the differen-
tiation of Tr1 cells induced with nasal anti-CD3: Tr1 differenti-
ation is defective in Ahr
d/tiger and IL-21R deficient mice following
Figure 3. Tr1 cells induced by nasal anti-CD3 express ahr, cmaf, il21 and il21r. A. Naive CD4+ T cells (CD4+CD25-GFP(IL-10)-), nTregs
(CD4+CD25+GFP(foxp3)+) sorted from Foxp3-GFP knock-in mice, ex vivo Tr1 cells (CD4+CD25-GFP(IL10)+) sorted from CLN of nasal anti-CD3 treated
Tiger mice and in vitro differentiated Tr1 using plate bound anti-CD3 and anti-CD28 plus 50 ng/ml IL-27 were used in quantitative RTPCR reactions.
Expressions of IL-10, IFN-c and foxp3 mRNA were normalized to expression of b-actin. B. AHR, C. cMAF, D. IL-21 and E. IL-21R mRNA expression by
CD4+GFP(IL-10)- T cells or CD4+GFP(IL-10)+ Tr1 cells. These experiments were repeated 3 times with same results.
doi:10.1371/journal.pone.0023618.g003
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with recombinant IL-21 significantly boosts the induction of Tr1
cells. These findings are consistent with our recent in vitro studies
[17,18], and demonstrate that AHR and Il-21 mediate the
induction of Tr1 cells triggered by nasally administered anti-CD3.
Moreover, they suggest that recombinant IL-21 can be used as an
adjuvant to potentiate the induction of suppressive Tr1 cells by
nasally administered anti-CD3.
In summary, our data supports a model in which upon
stimulation by nasal anti-CD3, resident DCs conditioned by the
nasal epithelia secrete IL-27, which promotes the differentiation of
Tr1 cells. IL-27R ligation triggers the synthesis of AHR and c-
MAF, which then bind and transactivate the il10 and il21
promoters [17,18]. Finally, IL-21 acts in an autocrine fashion to
further upregulate cMAF expression thus expands Tr1 cells in vivo
[13,17,22] (and fig.6). Our results identify a previously unknown
function of mucosal DCs in the upper airways and demonstrate
that nasal anti-CD3 is a unique approach to generate functional
suppressive Tr1 cells in vivo that control ongoing autoimmunity.
These findings identify nasal anti-CD3 as a novel therapeutic
approach for the treatment of autoimmune diseases.
Materials and Methods
Mice
B6, MRL/lpr, DTR-GFP CD11c, Foxp3-GFP knock-in, Ahr
d
and tiger mice were purchased from Jackson Laboratory (Bar
Harbor, Maine, USA). IL-27 receptor deficient (IL-27R
2/2) mice
were a generous gift from Vijay K. Kuchroo (Harvard Medical
School). IL-21 receptor deficient (IL-21R2/2) mice were a
generous gift from Warren Leonard (NIH) and Derry Roopenian
(Jackson Laboratory). IL-27R
2/2/lpr and Ahr
d/tiger mice were
bred and maintained at our facility at the Harvard Institutes of
Medicine. Only female mice were used in lupus studies. All mice
were housed in specific pathogen-free environment according to
the animal protocol guidelines of the Committee on Animals of
Harvard Medical School (Protocol No. 02683), which also
approved the experiments.
Antibodies, antigens and nasal treatment
Antibodies specific to CD3 (145-2c11) and CD28 (37.51) (BD
Biosciences, CA, USA) were used to stimulate T cells in vitro.
Neutralizing anti-mouse IL-10 (JES5-2A5), TGF-b (1D11), IL-4
Figure 4. The induction of Tr1 cells by nasal anti-CD3 requires AHR and IL-21 signaling. A. Tiger or Ahr
d/tiger mice were nasally treated
with IC or anti-CD3 and 72 hrs after the last nasal dose GFP(IL-10) expression by CD4+ T cells in CLN was examined by flow cytometry. Each symbol
represents an individual mouse. B. Tiger mice were nasally treated with IC or anti-CD3 alone or together with recombinant mouse IL-21 (4 mg/day). C.
WT or IL-21R2/2 mice were nasally treated with IC or anti-CD3.
doi:10.1371/journal.pone.0023618.g004
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antibodies were purchased from BioXCell, NH, USA. Neutraliz-
ing anti-mouse IL-27p28 and IL-21 antibody and mouse
recombinant IL-4, IL-6, IL-12, IL-21 and TGF-b was purchased
from R&D Systems, MN, USA. Fluorescent anti-mouse antibodies
used in flow cytometry were CD4-specific (H129.19), CD25-
specific (PC61) and IL-10 (JES5-16E3) (BD Biosciences). For Fcc
receptor blocking we used CD16/CD32-specific antibody (all
from BD Biosciences). Anti-mouse LAP monoclonal antibody
(16B4) was a kind gift from Taka Oida (Center for Neurologic
Disease). Anti-mouse Foxp3 (FJK-16s) antibody was purchased
from Ebiosciences, CA, USA. In studies of Tr1 cell generation in
vivo, mice were nasally treated with 5 consecutive doses of 0.5 mg
hamster IgG CD3-specific antibody (clone 145-2C11) or hamster
IgG control antibody (BioXCell) dissolved in PBS. Diphtheria
toxin was purchased from Sigma-Aldrich. LPS and FLT3 ligand
were purchased from R&D Systems.
T cell proliferation
Cells were cultured in triplicates at 1.5610
6/ml in the presence
of various amounts of antibodies or alone in 96-well round bottom
microtiter plates (Corning, NY, USA) for 96 hrs at 37uc with 5%
CO2 in a humid incubator. CD4
+ T cells were separated from
murine lymphoid organs using MACS CD4 purification kit
(Miltenyi Biotec). The purity of selected cells was checked by flow
cytometry. In all experiments, selection efficiency was over 90%.
For cell sorting CD4
+ T cells or whole lymphocytes were stained
with fluorescent anti-mouse LAP, CD4 and CD25 monoclonal
antibodies (all at 0.5 mg per million cells). CD4+ CD25- or + LAP-
or + GFP- or + T cells were sorted using a FACSVantage SE (BD
Biosciences). The purity of each population was .95% by flow
cytometric analysis. Tr1 and Th subset in vitro differentiation was
carried out in the present of plate bound anti-CD3 and anti-CD28
and relevant cytokine for 48 hrs followed by passage and 2
additional rounds of 48 hr culture. Tissue culture medium was
RPMI-1640 with 4.5 g/L glucose and L-Glutamine (BioWhit-
taker, MD, USA) supplemented with 2% penicillin and strepto-
mycin (BioWhittaker) and 1% fetal calf serum. Cultures were
pulsed with 0.25 mci tritiated thymidine ([
3H]d Thd; PerkinElmer,
MA, USA) for the last 6 hrs. [
3H]d Thd incorporation was
measured using a liquid scintillation beta counter (Wallac,
PerkinElmer).
Figure 5. Tr1 cells induced by nasal anti-CD3 in an IL-27-dependent manner control systemic autoimmunity. A. 8 wks old female MRL/
lpr or IL-27R2/2/lpr mice were nasally treated with 0.5 mg IC or anti-CD3. CLN cells were harvested at 72 hrs after the last nasal dose and stained
with anti-CD4 and anti-LAP antibodies. B. CD4+ T cells were isolated by positive selection and stimulated with plate bound anti-CD3 and anti-CD28
antibodies (1 mg/ml each) for 96 hrs. Culture supernatant was used in detection of IL-2, IL-5, IL10, IL-12 and IFN-c by ELISA. C. 4-wk old MRL/lpr or IL-
27R2/2/lpr mice (n=10) received three 5-day courses of 0.5 mg IC or anti-CD3 given at alternative weeks. Survival of mice following treatment was
followed for 40wks. D. Serum was collected from MRL/lpr, IL-27R2/+/lpr, IL-27R2/2/lpr or IL-27R2/2/lpr recipients of CD4+LAP- or CD4+ T cells. IgG
anti-dsDNA autoantibodies were detected by ELISA. E. 8 wk old female MRL/lpr mice were nasally treated with anti-CD3 for 5 consecutive days.
72 hrs after the last nasal dose CD4+ (red line) or CD4+LAP- (yellow line) T cells were sorted from CLN cells and adoptively transferred (1610
6 cells/
mouse) to 4-wk old IL-27R2/2/lpr recipients (n=10). Survival of recipients was followed for 40wks and compared to MRL/lpr (black line), IL-27R2/+/
lpr (blue line) or IL-27R2/2/lpr (green line) mice (n=10) without cell transfer. F. CD4+ T cells from IL-27R2/2/lpr recipients of CD4+LAP- (clear bars)
or CD4+ (filled bars) T cells were stimulated with plate bound anti-CD3 and anti-CD28 antibodies for 96 hrs. IL-12 and IFN-c in culture supernatant
was detected by ELISA.
doi:10.1371/journal.pone.0023618.g005
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Frozen sections of cervical lymph node or spleen (5 mM) were
air dried from 280uc for 30 mins and then fixed in 100% alcohol
for 1 min. Sections were washed twice with PBS and non-specific
binding sites were blocked with 10% normal rat serum in PBS for
1 hr at RT. Following 2 further washes with PBS, tissue sections
were stained with Toprol-3 (Invitrogen, CA, USA). Tissues
sections were analyzed by confocal microscopy.
Cytokine detection
The level of cytokines produced in vitro by cell cultures was
determined using BD OptEIA ELISA and reagent set (BD
Biosciences). Samples were tested in triplicate using the manufac-
turer’s recommended assay procedure. Cell culture supernatant
was harvested at different time points (48 hrs for IL-10; 96 hrs for
IL-2, IL-5, IL-12 and IFN-c) for the detection of cytokines.
Flow cytometry
Cells were washed (1200 RPM, 5 mins at 4uc) with PBS
containing 2% bovine serum albumin in PBS (PBS/BSA,
BioWhittaker). Fcc receptors were blocked by incubation with
anti-CD16/CD32 antibody for 30 mins at 4uc. Cells were washed
twice before being stained with fluorescent anti-mouse cell surface
molecule antibodies (1 mg/10
6 cells/test) or relevant IC antibody
for 30 min at 4uc in dark. After staining, cells were washed again
with PBS/BSA before flow cytometry (FACScan
TM, Becton
Dickson, NJ, USA). For intracellular staining, cells
(10610
6 cells/ml) in culture medium containing 1 ml GolgiSTOP
(BD Biosciences) were stimulated with PMA (50 ng/ml) and
ionomycin (1000 ng/ml) for 4 hrs at 37uc with 5% CO2 in a
humid incubator. After incubation cells were fixed and permea-
bilized before being stained. All FACs data was analyzed using
FlowJo software (TreeStar).
Serum ELISA
Autoantibodies were measured as described previously (14).
Briefly, double stranded DNA (dsDNA) was used at 20 mg/ml. For
the detection of total IgG, 50 ml/well of HRP-conjugated rat anti-
mouse antibody (BD Biosciences) at 0.001 mg/ml was added and
incubated at 37uc for 1 hr.
Quantitative RTPCR
RNA was extracted from FACS-sorted cells or in vitro
differentiated cells using RNAeasy columns (Qiagen, CA, USA).
cDNA was transcribed as recommended (Applied Biosystems, CA,
USA). The amount of cDNA was measured and equal amount of
cDNA from samples was used for quantitative RTPCR.All primer/
probe mixtures were obtained from Applied Biosystems. Taqman
analysis was performed on AB 7500 Fast System (Applied
Biosystems). Gene expression was normalized to b-actin expression.
Adoptive transfer
To test the in vivo regulatory function of LAP+ T cells we
transferred freshly isolated whole CD4
+ or CD4
+ T cells depleted
of LAP+ cells from nasal anti-CD3 treated MRL/lpr donors to 4-
wk old IL-27
2/2/lpr recipients. Each recipient received 1610
6 T
cells intravenously. We followed the recipients for 40 weeks and
recorded their survival rate.
Figure 6. A model for Tr1 cell generation by nasal anti-CD3. Nasal anti-CD3 triggers T cell activation via TCR/CD3 complex. T cell activation in
the presence of IL-27 secreted by local DCs in the CLN leads to activation of AHR and cMAF, which cooperate to transactivate the il10 and il21
promoters and promote IL-10 and IL-21 production. IL-21 then acts as a Tr1 growth factor in an autocrine fashion.
doi:10.1371/journal.pone.0023618.g006
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Statistical differences in cell proliferation and cytokine levels
were derived from 2-way ANNOVA test. We used Students’t-test
on circulating IgG levels. The Wilcoxon rank sum test was used for
all pair-wise group comparisons. A P value less than 0.05 is
considered significant.
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